1、 附錄五：肝癌臨床分期及治療路線圖附錄六：原發性肝癌診療規范（2017年版）編寫專家委員會名譽主任委員：吳孟超湯釗猷劉允怡陳孝平王學浩孫燕鄭樹森主任委員：樊嘉副主任委員：秦叔逵沈鋒李強董家鴻周儉王偉林蔡建強滕皋軍外科學組組長：周儉；副組長：楊甲梅別平劉連新文天夫介入治療學組組長：王建華；副組長：韓國宏王茂強劉瑞寶陸驪工內科及局部治療組組長：秦叔逵；副組長：任正剛陳敏山曾昭沖梁萍影像學組組長：曾蒙蘇；副組長：梁長虹陳敏嚴福華王文平病理學組組長：叢文銘；副組長：紀元委員（按姓氏拼音排序）：成文武戴朝六莢衛東李亞明李曄雄梁軍劉天舒呂國悅毛一雷任偉新石洪成孫惠川王文濤王曉穎邢寶才徐建明楊建勇楊業發葉勝

2、龍尹震宇張博恒張水軍周偉平朱繼業秘書長:孫惠川王征秘書:劉嶸史穎弘肖永勝代智七、參考文獻：1.TorreLA,BrayF,SiegelRL,FerlayJ,Lortet-TieulentJ,JemalA.Globalcancerstatistics,2012.CACancerJClin2015;65:87-108.ChenW,ZhengR,BaadePD,etal.CancerstatisticsinChina,2015.CACancerJClin2016;66:115-32.ZhangBH,YangBH,TangZY.Randomizedcontrolledtrialofscreeningf

3、orhepatocellularcarcinoma.JCancerResClinOncol2004;130:417-22.ZengMS,YeHY,GuoL,etal.Gd-EOB-DTPA-enhancedmagneticresonanceimagingforfocalliverlesionsinChinesepatients:amulticenter,open-label,phaseIIIstudy.HepatobiliaryPancreatDisInt2013;12:607-16.LeeYJ,LeeJM,LeeJS,etal.Hepatocellularcarcinoma:diagnost

4、icperformanceofmultidetectorCTandMRimaging-asystematicreviewandmeta-analysis.Radiology2015;275:97-109.IchikawaT,SaitoK,YoshiokaN,etal.Detectionandcharacterizationoffocalliverlesions:aJapanesephaseIII,multicentercomparisonbetweengadoxeticaciddisodium-enhancedmagneticresonanceimagingandcontrast-enhanc

5、edcomputedtomographypredominantlyinpatientswithhepatocellularcarcinomaandchronicliverdisease.InvestRadiol2010;45:133-41.丁鶯，陳財忠，饒圣祥，曾蒙蘇.Gd+-EOB-DTPA與Gd+-DTPA增強磁共振檢查肝細胞癌的對照研究中華普通外科雜志2013;28:682-5.YooSH,ChoiJY,JangJW,etal.Gd-EOB-DTPA-enhancedMRIisbetterthanMDCTindecisionmakingofcurativetreatmentforhepa

6、tocellularcarcinoma.AnnSurgOncol2013;20:2893-900.ChenCZ，RaoSX，DingY，etal.Hepatocellularcarcinoma20mmorsmallerincirrhosispatients:earlymagneticresonanceenhancementbygadoxeticacidcomparedwithgadopentetatedimeglumine.HepatolInt2014;8:104-11.ChenBB，MurakamiT，ShihTT，etal.Novelimagingdiagnosisforhepatocel

7、lularcarcinoma:consensusfromthe5thAsia-PacificPrimaryLiverCancerExpertMeeting(APPLE2014).LiverCancer2015;4:215-27.MerkleEM，ZechCJ，BartolozziC，etal.Consensusreportfromthe7thInternationalForumforLiverMagneticResonanceImaging.EurRadiol2016;26:674-82.ParkJW，KimJH，KimSK，etal.Aprospectiveevaluationof18F-F

8、DGand11C-acetatePET/CTfordetectionofprimaryandmetastatichepatocellularcarcinoma.JNuclMed2008;49:1912-21.LinCY，ChenJH，LiangJA，LinCC，JengLB，KaoCH.18F-FDGPETorPET/CTfordetectingextrahepaticmetastasesorrecurrenthepatocellularcarcinoma:asystematicreviewandmeta-analysis.EurJRadiol2012;81:2417-22.Boellaard

9、R，Delgado-BoltonR，OyenWJ，etal.FDGPET/CT:EANMprocedureguidelinesfortumourimaging:version2.0.EurJNuclMedMolImaging2015;42:328-54.BoellaardR，ODohertyMJ，WeberWA，etal.FDGPETandPET/CT:EANMprocedureguidelinesfortumourPETimaging:version1.0.EurJNuclMedMolImaging2010;37:181-200.WahlRL,JaceneH,KasamonY,LodgeMA

10、.FromRECISTtoPERCIST:EvolvingConsiderationsforPETresponsecriteriainsolidtumors.JNuclMed2009;50Suppl1:122S-50S.ChalianH,ToreHG,HorowitzJM,SalemR,MillerFH,YaghmaiV.Radiologicassessmentofresponsetotherapy:comparisonofRECISTVersions1.1and1.0.Radiographics2011;31:2093-105.FerdaJ,FerdovaE,BaxaJ,etal.Thero

11、leof18F-FDGaccumulationandarterialenhancementasbiomarkersintheassessmentoftyping,gradingandstagingofhepatocellularcarcinomausing18F-FDG-PET/CTwithintegrateddual-phaseCTangiography.AnticancerRes2015;35:2241-6.LeeJW,OhJK,ChungYA,etal.PrognosticSignificanceof18F-FDGUptakeinHepatocellularCarcinomaTreate

12、dwithTransarterialChemoembolizationorConcurrentChemoradiotherapy:AMulticenterRetrospectiveCohortStudy.JNuclMed2016;57:509-16.HyunSH,EoJS,LeeJW,etal.Prognosticvalueof18F-fluorodeoxyglucosepositronemissiontomography/computedtomographyinpatientswithBarcelonaClinicLiverCancerstages0andAhepatocellularcar

13、cinomas:amulticenterretrospectivecohortstudy.EurJNuclMedMolImaging2016.BertagnaF,BertoliM,BosioG,etal.DiagnosticroleofradiolabelledcholinePETorPET/CTinhepatocellularcarcinoma:asystematicreviewandmeta-analysis.HepatolInt2014;8:493-500.CheungTT,HoCL,LoCM,etal.11C-acetateand18F-FDGPET/CTforclinicalstag

14、ingandselectionofpatientswithhepatocellularcarcinomaforlivertransplantationonthebasisofMilancriteria:surgeonsperspective.JNuclMed2013;54:192-200.ZhangY,ShiH,LiB,CaiL,GuY,XiuY.TheaddedvalueofSPECT/spiralCTinpatientswithequivocalbonymetastasisfromhepatocellularcarcinoma.Nuklearmedizin2015;54:255-61.Fo

15、rnerA,VilanaR,AyusoC,etal.Diagnosisofhepaticnodules20mmorsmallerincirrhosis:Prospectivevalidationofthenoninvasivediagnosticcriteriaforhepatocellularcarcinoma.Hepatology2008;47:97-104.25.陳孝平.肝惡性腫瘤.In:陳孝平,ed.外科學.第2版ed.北京:人民衛生出版社;2010:620.26.WestraWH,HrubanRH,PhelpsTH,IsacsonC.SurgicalPathologyDissecti

16、on:AnIllustratedGuide.NewYork:Springer;2003.27.NaraS,ShimadaK,SakamotoY,etal.Prognosticimpactofmarginalresectionforpatientswithsolitaryhepatocellularcarcinoma:evidencefrom570hepatectomies.Surgery2012;151:526-36.28.叢文銘.肝細胞性惡性腫瘤.In:叢文銘,ed.肝膽腫瘤外科病理學.1ed.北京:人民衛生出版社;2015:276-320.29.ScheuerPJ.Classificati

17、onofchronicviralhepatitis:aneedforreassessment.JHepatol1991;13:372-4.30.病毒性肝炎防治方案.中華傳染病雜志2001;19:56-62.31.GuidelinesforthePrevention,CareandTreatmentofPersonswithChronicHepatitisBInfection.Geneva2015.32.Rodriguez-PeralvarezM,LuongTV,AndreanaL,MeyerT,DhillonAP,BurroughsAK.Asystematicreviewofmicrovasc

18、ularinvasioninhepatocellularcarcinoma:diagnosticandprognosticvariability.AnnSurgOncol2013;20:325-39.33.中國抗癌協會肝癌專業委員會,中華醫學會肝病學分會肝癌學組,中國抗癌協會病理專業委員會,etal.原發性肝癌規范化病理診斷指南（2015年版）.中華肝膽外科雜志2015;21:145-51.EguchiS,TakatsukiM,HidakaM,etal.Predictorforhistologicalmicrovascularinvasionofhepatocellularcarcinoma:

19、alessonfrom229consecutivecasesofcurativeliverresection.WorldJSurg2010;34:1034-8.FujitaN,AishimaS,IguchiT,etal.Histologicclassificationofmicroscopicportalvenousinvasiontopredictprognosisinhepatocellularcarcinoma.HumPathol2011;42:1531-8.IguchiT,ShirabeK,AishimaS,etal.NewPathologicStratificationofMicro

20、vascularInvasioninHepatocellularCarcinoma:PredictingPrognosisAfterLiving-donorLiverTransplantation.Transplantation2015;99:1236-42.ImamuraH,SeyamaY,KokudoN,etal.Onethousandfifty-sixhepatectomieswithoutmortalityin8years.ArchSurg2003;138:1198-206;discussion206.KubotaK,MakuuchiM,KusakaK,etal.Measurement

21、oflivervolumeandhepaticfunctionalreserveasaguidetodecision-makinginresectionalsurgeryforhepatictumors.Hepatology1997;26:1176-81.BruixJ,CastellsA,BoschJ,etal.Surgicalresectionofhepatocellularcarcinomaincirrhoticpatients:prognosticvalueofpreoperativeportalpressure.Gastroenterology1996;111:1018-22.Cesc

22、onM,ColecchiaA,CucchettiA,etal.ValueoftransientelastographymeasuredwithFibroScaninpredictingtheoutcomeofhepaticresectionforhepatocellularcarcinoma.AnnSurg2012;256:706-12;discussion12-3.ChenMS,LiJQ,ZhengY,etal.Aprospectiverandomizedtrialcomparingpercutaneouslocalablativetherapyandpartialhepatectomyfo

23、rsmallhepatocellularcarcinoma.AnnSurg2006;243:321-8.LiuPH,HsuCY,HsiaCY,etal.SurgicalResectionVersusRadiofrequencyAblationforSingleHepatocellularCarcinoma/=5cm)HepatocellularCarcinoma:MicrowaveAblationImmediatelyFollowedbyTransarterialChemoembolization.JVascIntervRadiol2016.ZengZC,TangZY,FanJ,etal.Ac

24、omparisonofchemoembolizationcombinationwithandwithoutradiotherapyforunresectablehepatocellularcarcinoma.CancerJ2004;10:307-16.MengMB,CuiYL,LuY,etal.Transcatheterarterialchemoembolizationincombinationwithradiotherapyforunresectablehepatocellularcarcinoma:asystematicreviewandmeta-analysis.RadiotherOnc

25、ol2009;92:184-94.ZengZC,FanJ,TangZY,etal.Acomparisonoftreatmentcombinationswithandwithoutradiotherapyforhepatocellularcarcinomawithportalveinand/orinferiorvenacavatumorthrombus.IntJRadiatOncolBiolPhys2005;61:432-43.ZengZC,TangZY,FanJ,etal.Considerationofroleofradiotherapyforlymphnodemetastasesinpati

26、entswithHCC:retrospectiveanalysisforprognosticfactorsfrom125patients.IntJRadiatOncolBiolPhys2005;63:1067-76.ZhouLY,ZengZC,FanJ,etal.Radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinoma:clinicalfeaturesandprognosticfactors.BmcCancer2014;14:878-87.HeJ,ZengZC,TangZY,etal.Clinicalfea

27、turesandprognosticfactorsinpatientswithbonemetastasesfromhepatocellularcarcinomareceivingexternalbeamradiotherapy.Cancer2009;115:2710-20.WangWH,WangZ,WuJX,etal.SurvivalbenefitwithIMRTfollowingnarrow-marginhepatectomyinpatientswithhepatocellularcarcinomaclosetomajorvessels.LiverInt2015;35:2603-10.Wan

28、gMH,JiY,ZengZC,etal.Impactfactorsformicroinvasioninpatientswithhepatocellularcarcinoma:possibleapplicationtothedefinitionofclinicaltumorvolume.IntJRadiatOncolBiolPhys2010;76:467-76.101.曾昭沖.肝細胞癌的立體定向放射治療.中華腫瘤雜志2015:650-2,3.DawsonLA,NormolleD,BalterJM,McGinnCJ,LawrenceTS,TenHakenRK.Analysisofradiation

29、-inducedliverdiseaseusingtheLymanNTCPmodel.IntJRadiatOncolBiolPhys2002;53:810-21.LiangSX,ZhuXD,XuZY,etal.Radiation-inducedliverdiseaseinthree-dimensionalconformalradiationtherapyforprimarylivercarcinoma:theriskfactorsandhepaticradiationtolerance.IntJRadiatOncolBiolPhys2006;65:426-34.ChonYE,SeongJ,Ki

30、mBK,etal.Gastroduodenalcomplicationsafterconcurrentchemoradiationtherapyinpatientswithhepatocellularcarcinoma:endoscopicfindingsandriskfactors.IntJRadiatOncolBiolPhys2011;81:1343-51.HouJZ,ZengZC,WangBL,YangP,ZhangJY,MoHF.Highdoseradiotherapywithimage-guidedhypo-IMRTforhepatocellularcarcinomawithport

31、alveinand/orinferiorvenacavatumorthrombiismorefeasibleandefficaciousthanconventional3D-CRT.JpnJClinOncol2016;46:357-62.HuY,ZhouYK,ChenYX,ShiSM,ZengZC.4D-CTscansrevealreducedmagnitudeofrespiratorylivermotionachievedbydifferentabdominalcompressionplatepositionsinpatientswithintrahepatictumorsundergoin

32、ghelicaltomotherapy.MedPhys2016;43:4335.LauWY,TeohYL,WinKM,etal.Currentroleofselectiveinternalradiationwithyttrium-90inlivertumors.FutureOncol2016;12:1193-204.XuJ,ShenZY,ChenXG,etal.ArandomizedcontrolledtrialofLicartinforpreventinghepatomarecurrenceafterlivertransplantation.Hepatology2007;45:269-76.

33、RaoulJL,GuyaderD,BretagneJF,etal.Randomizedcontrolledtrialforhepatocellularcarcinomawithportalveinthrombosis:intra-arterialiodine-131-iodizedoilversusmedicalsupport.JNuclMed1994;35:1782-7.LlovetJM,RicciS,MazzaferroV,etal.Sorafenibinadvancedhepatocellularcarcinoma.NEnglJMed2008;359:378-90.PressianiT,

34、BoniC,RimassaL,etal.SorafenibinpatientswithChild-PughclassAandBadvancedhepatocellularcarcinoma:aprospectivefeasibilityanalysis.AnnOncol2013;24:406-11.QinS,BaiY,LimHY,etal.Randomized,multicenter,open-labelstudyofoxaliplatinplusfluorouracil/leucovorinversusdoxorubicinaspalliativechemotherapyinpatientswithadvancedhepatocellularcarcinomafromAsia.JClinOncol2013;31:3501-8.LeeJH,LeeJH,LimYS,et